Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
Aims: To evaluate the efficacy of re-resection in recurrent hepatocellular carcinoma (rHCC), identify prognostic factors, and provide clinical guidance. Methods: A retrospective analysis was conducted on 130 rHCC patients undergoing re-resection and 60 primary HCC patients undergoing initial hepatec...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Surgery Open Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589845024001404 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576439490183168 |
|---|---|
| author | Qi Fan, MM Pengcheng Wei, MM Delin Ma, MD Qian Cheng, MD Jie Gao, MD Jiye Zhu, MD Zhao Li, MD |
| author_facet | Qi Fan, MM Pengcheng Wei, MM Delin Ma, MD Qian Cheng, MD Jie Gao, MD Jiye Zhu, MD Zhao Li, MD |
| author_sort | Qi Fan, MM |
| collection | DOAJ |
| description | Aims: To evaluate the efficacy of re-resection in recurrent hepatocellular carcinoma (rHCC), identify prognostic factors, and provide clinical guidance. Methods: A retrospective analysis was conducted on 130 rHCC patients undergoing re-resection and 60 primary HCC patients undergoing initial hepatectomy at Peking University People's Hospital (2014–2022). Disease-free survival (DFS) and overall survival (OS) were compared. Prognostic factors were identified using univariate and multivariate COX regression analyses. Results: Baseline characteristics were comparable between groups (P > 0.05). DFS was similar between groups (30.8 vs. 32.2 months, P = 0.612). The 1-year, 2-year, and 3-year DFS rates for the re-resection group were 88.5 %, 64.9 %, and 56.7 %, respectively, versus 88.3 %, 65.0 %, and 53.3 % for the primary resection group. OS was lower in the re-resection group (36.1 vs. 47.2 months, P = 0.041) with 1-year, 2-year, and 3-year OS rates of 90.8 %, 73.1 %, and 60.0 %, compared to 95.0 %, 80.0 %, and 68.3 % for the primary resection group. Significant factors affecting DFS were Child-Pugh classification (P = 0.044), time to recurrence (P = 0.002), tumor differentiation (P = 0.044), and satellite nodules (P = 0.019). Factors influencing OS included Child-Pugh classification (P = 0.040), time to recurrence (P = 0.002), and tumor differentiation (P = 0.032). Conclusions: Re-resection is an effective treatment option for rHCC, with favorable outcomes as measured by DFS and OS, though OS is lower compared to initial hepatectomy. Key prognostic factors include Child-Pugh classification, time to recurrence, tumor differentiation, and satellite nodules. |
| format | Article |
| id | doaj-art-ccc8486fc3214dbab94a20d7eb41ec7c |
| institution | Kabale University |
| issn | 2589-8450 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Surgery Open Science |
| spelling | doaj-art-ccc8486fc3214dbab94a20d7eb41ec7c2025-01-31T05:12:14ZengElsevierSurgery Open Science2589-84502025-01-01231623Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective studyQi Fan, MM0Pengcheng Wei, MM1Delin Ma, MD2Qian Cheng, MD3Jie Gao, MD4Jiye Zhu, MD5Zhao Li, MD6Department of General Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, China; Peking University Institute of Organ Transplantation, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, China; Peking University Institute of Organ Transplantation, Beijing, ChinaDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China; Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer, Beijing, China; Peking University Center of Liver Cancer Diagnosis and Treatment, Beijing, China; Peking University Institute of Organ Transplantation, Beijing, China; Corresponding author at: Department of Hepatobiliary Surgery, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing 100044, China.Aims: To evaluate the efficacy of re-resection in recurrent hepatocellular carcinoma (rHCC), identify prognostic factors, and provide clinical guidance. Methods: A retrospective analysis was conducted on 130 rHCC patients undergoing re-resection and 60 primary HCC patients undergoing initial hepatectomy at Peking University People's Hospital (2014–2022). Disease-free survival (DFS) and overall survival (OS) were compared. Prognostic factors were identified using univariate and multivariate COX regression analyses. Results: Baseline characteristics were comparable between groups (P > 0.05). DFS was similar between groups (30.8 vs. 32.2 months, P = 0.612). The 1-year, 2-year, and 3-year DFS rates for the re-resection group were 88.5 %, 64.9 %, and 56.7 %, respectively, versus 88.3 %, 65.0 %, and 53.3 % for the primary resection group. OS was lower in the re-resection group (36.1 vs. 47.2 months, P = 0.041) with 1-year, 2-year, and 3-year OS rates of 90.8 %, 73.1 %, and 60.0 %, compared to 95.0 %, 80.0 %, and 68.3 % for the primary resection group. Significant factors affecting DFS were Child-Pugh classification (P = 0.044), time to recurrence (P = 0.002), tumor differentiation (P = 0.044), and satellite nodules (P = 0.019). Factors influencing OS included Child-Pugh classification (P = 0.040), time to recurrence (P = 0.002), and tumor differentiation (P = 0.032). Conclusions: Re-resection is an effective treatment option for rHCC, with favorable outcomes as measured by DFS and OS, though OS is lower compared to initial hepatectomy. Key prognostic factors include Child-Pugh classification, time to recurrence, tumor differentiation, and satellite nodules.http://www.sciencedirect.com/science/article/pii/S2589845024001404Recurrent hepatocellular carcinomaRe-resectionPrognosisSurvival analysisImmune microenvironment |
| spellingShingle | Qi Fan, MM Pengcheng Wei, MM Delin Ma, MD Qian Cheng, MD Jie Gao, MD Jiye Zhu, MD Zhao Li, MD Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study Surgery Open Science Recurrent hepatocellular carcinoma Re-resection Prognosis Survival analysis Immune microenvironment |
| title | Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study |
| title_full | Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study |
| title_fullStr | Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study |
| title_full_unstemmed | Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study |
| title_short | Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study |
| title_sort | therapeutic efficacy and prognostic indicators in re resection for recurrent hepatocellular carcinoma insights from a retrospective study |
| topic | Recurrent hepatocellular carcinoma Re-resection Prognosis Survival analysis Immune microenvironment |
| url | http://www.sciencedirect.com/science/article/pii/S2589845024001404 |
| work_keys_str_mv | AT qifanmm therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy AT pengchengweimm therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy AT delinmamd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy AT qianchengmd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy AT jiegaomd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy AT jiyezhumd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy AT zhaolimd therapeuticefficacyandprognosticindicatorsinreresectionforrecurrenthepatocellularcarcinomainsightsfromaretrospectivestudy |